This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-07-0212v1 67/11/5569    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lim, U. Articles by Albanes, D. Search for Related Content PubMed PubMed Citation Articles by Lim, U. Articles by Albanes, D.

Serum High-Density Lipoprotein Cholesterol and Risk of Non-Hodgkin Lymphoma

¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Rockville, Maryland; ² University of Illinois College of Medicine, Urbana-Champaign, Illinois; and ³ Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki, Finland

Requests for reprints: Unhee Lim, Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS 320, Rockville, MD 20852. Phone: 301-451-9624; Fax: 301-496-6829; E-mail: limu{at}mail.nih.gov.

Lymphoma patients often exhibit abnormal lipid metabolism. Recent evidence, however, suggests that a decrease in circulating high-density lipoprotein cholesterol (HDL-C) may occur during lymphomagenesis, reflecting underlying etiology such as inflammation. We investigated the relationship between prediagnostic HDL-C and non-Hodgkin lymphoma (NHL) in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study cohort. At baseline, serum HDL-C and total cholesterol concentrations from fasting blood, information on diet and lifestyle, and direct measurements of height, weight, and blood pressure were obtained from 27,074 healthy male smokers of ages 50 to 69 years. Cox proportional hazards models with age as underlying time metric was used to estimate relative risks (RR) and 95% confidence intervals (95% CI). We found no association between total or non-HDL cholesterol and the 201 incident NHL cases ascertained during the follow-up (1985–2002), but observed an inverse association between HDL-C and NHL, which changed with length of follow-up. High HDL-C was associated with lower risk of all NHL during the first 10 years (n = 148; RR for 5th versus 1st quintile, 0.35; 95% CI, 0.19–0.62; P_trend < 0.0001), but not with diagnoses during later follow-up (n = 53; RR, 1.31; 95% CI, 0.55–3.10). The inverse association was similar for NHL subtypes and was not modified by obesity, blood pressure, physical activity, or alcohol intake, but seemed to be stronger in men with lower duration of smoking (P_interaction = 0.06). Our findings implicate HDL-C as a preclinical indicator of NHL and warrant further prospective investigations for its etiologic contribution. [Cancer Res 2007;67(11):5569–74]

This article has been cited by other articles:

				A. M. Strasak, R. M. Pfeiffer, L. J. Brant, K. Rapp, W. Hilbe, W. Oberaigner, S. Lang, W. Borena, H. Concin, G. Diem, et al. Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172 210 men and women: a prospective 19-year follow-up study Ann. Onc., June 1, 2009; 20(6): 1113 - 1120. [Abstract] [Full Text] [PDF]